Crossmark

The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada

Crossref DOI link: https://doi.org/10.1186/s12913-025-12207-9

Published Online: 2025-01-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hong, Jihyung

Bae, Eun-Young

Cha, Sohee

Lee, Joohyun
Funding

Funding for this research was provided by:

National Health Insurance Service

National Research Foundation of Korea (No.2022R1A2C1012252, No.2022R1A2C1012252, No.2022R1A2C1012252)
License Information

Text and Data Mining valid from 2025-01-14

Version of Record valid from 2025-01-14
More Information

Article History

Received: 19 October 2023

Accepted: 1 January 2025

First Online: 14 January 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below